Current knowledge and future perspectives on acute hepatitis C infection

S. J. Hullegie; J. E. Arends; B. J A Rijnders; W. L. Irving; D. Salmon; M. Prins; A. M. Wensing; P. Klenerman; H. Leblebicioglu; C. Boesecke; J. K. Rockstroh; A. I M Hoepelman

doi:10.1016/j.cmi.2015.03.026

Current knowledge and future perspectives on acute hepatitis C infection

S. J. Hullegie, J. E. Arends^*, B. J A Rijnders, W. L. Irving, D. Salmon, M. Prins, A. M. Wensing, P. Klenerman, H. Leblebicioglu, C. Boesecke, J. K. Rockstroh, A. I M Hoepelman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Acute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between 0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and repeated HCV RNA measurements, although no definitive diagnostic test is currently available. Progress in the field of adaptive and innate immune responses has aided both advances in the field of HCV vaccine development and a more basic understanding of viral persistence. The rapid changes in the treatment of chronic HCV infection will affect therapeutic regimens for acute HCV infection in the coming years, leading to shorter treatment courses and pegylated interferon-free modalities. This review gives an overview of the current knowledge and uncertainties, together with some future perspectives on acute hepatitis C epidemiology, virology, immunology, and treatment.

Original language	English
Pages (from-to)	e797.e9-797.e17
Journal	Clinical Microbiology and Infection
Volume	21
Issue number	8
DOIs	https://doi.org/10.1016/j.cmi.2015.03.026
Publication status	Published - 1 Jan 2015

Keywords

Acute hepatitis C
Epidemiology
Immunology
Treatment
Virology

Access to Document

10.1016/j.cmi.2015.03.026

Cite this

Hullegie, S. J., Arends, J. E., Rijnders, B. J. A., Irving, W. L., Salmon, D., Prins, M., Wensing, A. M., Klenerman, P., Leblebicioglu, H., Boesecke, C., Rockstroh, J. K., & Hoepelman, A. I. M. (2015). Current knowledge and future perspectives on acute hepatitis C infection. Clinical Microbiology and Infection, 21(8), e797.e9-797.e17. https://doi.org/10.1016/j.cmi.2015.03.026

@article{053871da78e943fd96a9254a9eadd2ae,

title = "Current knowledge and future perspectives on acute hepatitis C infection",

abstract = "Acute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between 0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and repeated HCV RNA measurements, although no definitive diagnostic test is currently available. Progress in the field of adaptive and innate immune responses has aided both advances in the field of HCV vaccine development and a more basic understanding of viral persistence. The rapid changes in the treatment of chronic HCV infection will affect therapeutic regimens for acute HCV infection in the coming years, leading to shorter treatment courses and pegylated interferon-free modalities. This review gives an overview of the current knowledge and uncertainties, together with some future perspectives on acute hepatitis C epidemiology, virology, immunology, and treatment.",

keywords = "Acute hepatitis C, Epidemiology, Immunology, Treatment, Virology",

author = "Hullegie, {S. J.} and Arends, {J. E.} and Rijnders, {B. J A} and Irving, {W. L.} and D. Salmon and M. Prins and Wensing, {A. M.} and P. Klenerman and H. Leblebicioglu and C. Boesecke and Rockstroh, {J. K.} and Hoepelman, {A. I M}",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.cmi.2015.03.026",

language = "English",

volume = "21",

pages = "e797.e9--797.e17",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Current knowledge and future perspectives on acute hepatitis C infection

AU - Hullegie, S. J.

AU - Arends, J. E.

AU - Rijnders, B. J A

AU - Irving, W. L.

AU - Salmon, D.

AU - Prins, M.

AU - Wensing, A. M.

AU - Klenerman, P.

AU - Leblebicioglu, H.

AU - Boesecke, C.

AU - Rockstroh, J. K.

AU - Hoepelman, A. I M

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Acute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between 0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and repeated HCV RNA measurements, although no definitive diagnostic test is currently available. Progress in the field of adaptive and innate immune responses has aided both advances in the field of HCV vaccine development and a more basic understanding of viral persistence. The rapid changes in the treatment of chronic HCV infection will affect therapeutic regimens for acute HCV infection in the coming years, leading to shorter treatment courses and pegylated interferon-free modalities. This review gives an overview of the current knowledge and uncertainties, together with some future perspectives on acute hepatitis C epidemiology, virology, immunology, and treatment.

AB - Acute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between 0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and repeated HCV RNA measurements, although no definitive diagnostic test is currently available. Progress in the field of adaptive and innate immune responses has aided both advances in the field of HCV vaccine development and a more basic understanding of viral persistence. The rapid changes in the treatment of chronic HCV infection will affect therapeutic regimens for acute HCV infection in the coming years, leading to shorter treatment courses and pegylated interferon-free modalities. This review gives an overview of the current knowledge and uncertainties, together with some future perspectives on acute hepatitis C epidemiology, virology, immunology, and treatment.

KW - Acute hepatitis C

KW - Epidemiology

KW - Immunology

KW - Treatment

KW - Virology

UR - http://www.scopus.com/inward/record.url?scp=84930260310&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2015.03.026

DO - 10.1016/j.cmi.2015.03.026

M3 - Article

C2 - 25892133

AN - SCOPUS:84930260310

SN - 1198-743X

VL - 21

SP - e797.e9-797.e17

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 8

ER -

Current knowledge and future perspectives on acute hepatitis C infection

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this